New Studies Show Kidney Drugs Benefit Very Old Patients

Medical researchers announced new data showing that older adults with chronic kidney disease experience lower mortality rates when treated with specific diabetes medications.

Investigators evaluated electronic health records for 10,076 patients aged 80 years or older over a duration of 2 years.

The analysis revealed an 18 percent drop in all-cause mortality alongside a 22 percent decrease in major adverse kidney events.

Cardiovascular outcomes showed no overall shift, although researchers noted elevated risks for heart attacks, acute heart failure, and acute kidney injury.

Medical trials frequently exclude geriatric patients due to frailty and multiple concurrent health conditions, leaving a major blind spot in existing literature.

Very old patients face historical exclusion from major clinical trials because of multiple illnesses and physical decline, according to study authors.

"Very elderly individuals are historically underrepresented in or systematically excluded from large-scale randomized controlled trials due to multimorbidity and frailty," said Bernhard M. W. Schmidt, corresponding author from Hannover Medical School.

"Even the oldest and most vulnerable CKD patients can derive substantial benefits from SGLT2 inhibitor treatment, but these medications may not be without risk in this demographic," said Schmidt.

A separate study presented at the same meeting examined 151,134 older adults in South Korea to evaluate outcomes among frail individuals.

That cohort demonstrated a 30 percent lower risk of composite kidney events and a 19 percent reduction in cardiovascular events among frail patients taking the drugs.

Despite proven advantages, a nationwide study found that over half of patients with diabetes and kidney damage receive neither sodium-glucose cotransporter 2 inhibitors nor receptor agonists.

Kamyar Kalantar-Zadeh, a professor at The Lundquist Institute, said the widespread failure to prescribe these beneficial medications stems from valid clinical caution rather than simple oversight.

"I believe this reflects a combination of legitimate clinical concerns and appropriate risk aversion," said Kalantar-Zadeh.

Medical experts urge clinics to integrate pharmacists into treatment teams to monitor kidney function, manage side effects, and optimize prescriptions.

Future medical guidelines will determine whether clinicians can safely expand these drug therapies to older and more vulnerable populations.